Evaluation and effective management of asthma, and in particular severe asthma, remains
at the core of pulmonary practice. Over the last 20–30 years, there has been increasing …

Severe asthma affects about 10% of the population with asthma and is characterized by low
lung function and a high count of blood leukocytes, mainly eosinophils. Various definitions …

Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Purpose Current guidelines primarily use medication levels to distinguish severe asthma
from other types of asthma. In addition, severe asthma must also be uncontrolled at high …

Severe asthma is “asthma which requires treatment with high dose inhaled corticosteroids
(ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming …

Background Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving
allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a …

Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence.
The underlying chronic inflammatory process and airway remodeling (AR) contribute to the …

Group-2 innate lymphoid cells (ILC2) are part of a growing family of innate lymphocytes
known for their crucial role in both the development and exacerbation of allergic asthma …

Allergic asthma has traditionally been treated with inhaled and systemic
glucocorticosteroids. A continuum of allergic fungal airways disease associated with …

Background Adult-onset asthma is associated with a poor treatment response. The aim was
to study associations between clinical characteristics, asthma control and treatment in adult …